Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

PF-3644022

Catalog No. T16501Cas No. 1276121-88-0

PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) (IC50s: 53 nM and 5.0 nM, respectively).

PF-3644022

PF-3644022

Purity: 98.13%
Catalog No. T16501Cas No. 1276121-88-0
PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) (IC50s: 53 nM and 5.0 nM, respectively).
Pack SizePriceAvailabilityQuantity
1 mg$31In Stock
5 mg$113In Stock
10 mg$213In Stock
25 mg$438In Stock
50 mg$653In Stock
100 mg$876In Stock
500 mg$1,750In Stock
1 mL x 10 mM (in DMSO)$196In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "PF-3644022"

Select Batch
Purity:98.13%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated/activated
Targets&IC50
PRAK:5.0 nM, MK2:(ki)3 nM, MK2:5.2 nM, MK3:53 nM
In vitro
PF-3644022 potently inhibits TNFα production with similar activity (IC50 of 160 nM), in the human U937 monocytic cell line or peripheral blood mononuclear cells. PF-3644022 blocks TNFα and IL-6 production in LPS-stimulated human whole blood (IC50: 1.6 and 10.3 μM, respectively). The inhibitory activity of PF-3644022 against other MAPKAP kinase family members is evaluated. Other than MNK2 with an IC50 of 148 nM, other family members are largely not inhibited, showing at least several hundred-fold selectivity versus MK2[1].
In vivo
PF-3644022 (3-100 mg/kg; oral gavage; twice daily for 12 days; Lewis rats) treatment exhibits dose-dependent inhibition of chronic paw swelling, measured on day 21 post-treatment (ED50: 20 mg/kg)[1].
Chemical Properties
Molecular Weight374.46
FormulaC21H18N4OS
Cas No.1276121-88-0
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 41.67 mg/mL (111.28 mM), Sonication and heating to 80℃ are recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.6705 mL13.3526 mL26.7051 mL133.5256 mL
5 mM0.5341 mL2.6705 mL5.3410 mL26.7051 mL
10 mM0.2671 mL1.3353 mL2.6705 mL13.3526 mL
20 mM0.1335 mL0.6676 mL1.3353 mL6.6763 mL
50 mM0.0534 mL0.2671 mL0.5341 mL2.6705 mL
100 mM0.0267 mL0.1335 mL0.2671 mL1.3353 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy PF-3644022 | purchase PF-3644022 | PF-3644022 cost | order PF-3644022 | PF-3644022 chemical structure | PF-3644022 in vivo | PF-3644022 in vitro | PF-3644022 formula | PF-3644022 molecular weight